The aim of this study is to evaluate the effect of giving adjuvant treatment with
intermediate doses of interferon-alpha2b to patients operated for high risk melanoma.
Patients are randomly assigned to either observation only or interferon treatment for 2
different durations. The outcome with respect to overall survival, relapse-free survival,
side effects and quality of life is analysed.